Amedisys (AMED) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amedisys Reports Second Quarter 2022 Financial Results and Updates 2022 Revenue Guidance
July 27, 2022 4:06 PM EDTBATON ROUGE, La., July 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2022.
Three-Month Periods Ended June 30, 2022 and 2021
Net service revenue decreased $6.3 million to $557.9 million compared to $564.2 million in 2021.Net income attributable to Amedisys, Inc. of $29.6 million compared to $80.1 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.91 compared to $2.43 in 2021.Adjusted... More
